KLRS
Kalaris Therapeutics, Inc. · Healthcare
Insiders bought $1.2M net in the last 90 days ·1 seller, 1 buyer· latest Form 4 filed May 22, 2026
Insider Buying
$6.2M
reported purchases (SEC code P)
Insider Selling
$13K
reported sales (SEC code S)
Unique Insiders
2
in the rolling window
Latest filing
May 22, 2026
AKKARAJU SRINIVAS
Kalaris Therapeutics, Inc. (KLRS) has 4 SEC Form 4 filings (7 transaction rows) in the rolling window, disclosed by 2 distinct insiders. Most recent filing: May 22, 2026.
Inside the rolling window, 2 insiders at Kalaris Therapeutics, Inc. reported 2 open-market purchases totaling $6.2M and 1 open-market sale totaling $13K. Insiders have net bought $6.2M over the trailing 6 months. The largest single insider purchase in this window was $5.0M by Director, 10% Owner AKKARAJU SRINIVAS on Dec 18, 2025. The most recent open-market filing is a purchase of 244,300 shares by Director, 10% Owner AKKARAJU SRINIVAS, dated May 20, 2026, worth $1.2M.
- Industry:Biotechnology
- CEO:Andrew Oxtoby
- Employees:20
- HQ:Berkeley Heights, NJ, US
- IPO:2020-07-30
| Source | |||||||
|---|---|---|---|---|---|---|---|
AKKARAJU SRINIVASFirst in 3 months | Director, 10% Owner | Purchase | 244,300 | $1.2M | May 22 | -18.1% | SEC ↗ |
Hagen Brett RFirst filing | Chief Accounting Officer | Sale | 1,915 | $13K | Mar 23 | -38.0% | SEC ↗ |
| Director, 10% Owner | Purchase | 479,847 | $5.0M | Feb 17 | -51.2% | SEC ↗ |
Earnings: last 7 quarters
Frequently asked questions
How many SEC Form 4 insider filings does KLRS have?
Kalaris Therapeutics, Inc. (KLRS) has 4 SEC Form 4 filings (7 transaction rows) in the rolling 365-day window, disclosed by 2 distinct insiders. Most recent filing: May 22, 2026.
When was the most recent SEC Form 4 filing for KLRS?
The most recent Form 4 filing for KLRS on Tracefour is dated May 22, 2026.
What is the net insider flow at KLRS over the last 6 months?
Over the trailing 180 days, insiders at KLRS have net bought $6.2M based on SEC Form 4 disclosures.
What was the largest insider purchase at KLRS?
The largest single insider open-market purchase at KLRS in the rolling window was $5.0M by Director, 10% Owner AKKARAJU SRINIVAS on 2025-12-18.
What is the total insider buy and sell value at KLRS in the current window?
Inside the rolling window, insiders at KLRS bought $6.2M and sold $13K based on SEC Form 4 filings.
Can I get alerts for KLRS insider trading?
Yes. Tracefour sends a free email when a new SEC Form 4 purchase or sale is filed at Kalaris Therapeutics, Inc. (KLRS). Alerts are set per company from the page itself, there is no paid tier, and each email links to the original filing on SEC EDGAR.
Related companies
Kalaris Therapeutics, Inc. is in the Healthcare sector.